Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.
Zevra Therapeutics, Inc. (symbol: ZVRA) is a pioneering rare disease company dedicated to developing transformational therapies for conditions with limited or no treatment options. By combining science, data, and patient needs, Zevra aims to deliver life-changing solutions to individuals living with rare diseases. Their mission is to address these unmet medical needs through unique, data-driven development and commercialization strategies.
Zevra Therapeutics utilizes its proprietary Ligand Activated Therapy (LAT) approach to create improved prodrug versions of FDA-approved medications. These prodrugs target high-need areas such as pain management, ADHD, and other central nervous system diseases. Through this innovative technology, Zevra is overcoming complex drug development challenges and making new therapies accessible to the rare disease community.
Recent achievements include significant advancements in their pipeline projects, particularly in pain and ADHD treatment. The company is also known for its strategic partnerships, which enhance its research and development capabilities and accelerate the commercialization of its therapies. Financially, Zevra has a solid foundation, allowing it to focus on its core mission of addressing rare diseases and improving patients' lives.
For up-to-date information, news, and latest developments, Zevra encourages stakeholders to stay connected through their official contact points:
- Nichol Ochsner: +1 (732) 754-2545, nochsner@zevra.com
- Russo Partners: David Schull: +1 (858) 717-2310, david.schull@russopartnersllc.com
- Russo Partners: Ignacio Guerrero-Ros, Ph.D.: +1 (646) 942-5604, ignacio.guerrero-ros@russopartnersllc.com
Zevra Therapeutics, Inc. (ZVRA) will participate in several investor events in May 2024, with Neil F. McFarlane, the President and CEO, presenting at conferences in New York and Boston. The company aims to engage with investors and provide updates on their rare disease therapeutics.
Zevra Therapeutics, Inc. reported its Q1 2024 financial results, including $3.4 million in revenue, increasing R&D and SG&A expenses, a net loss of ($16.6) million, and a cash balance of $52.7 million. The Company refinanced its debt, securing up to $100 million in committed capital.
Zevra Therapeutics, Inc. (ZVRA) will report Q1 2024 results on May 8, 2024. The rare disease therapeutics company will hold a conference call to discuss corporate and financial performance.
Zevra Therapeutics, Inc., a rare disease therapeutics company, releases a letter to stockholders by Neil F. McFarlane, President and CEO, highlighting key accomplishments and outlook for 2024. The letter emphasizes a patient-centric approach, team building, and progress in advancing rare disease therapies. The company's financial strength, governance enhancements, and future prospects are also discussed.
FAQ
What is the current stock price of Zevra Therapeutics (ZVRA)?
What is the market cap of Zevra Therapeutics (ZVRA)?
What does Zevra Therapeutics, Inc. specialize in?
What is the company's mission?
What is the Ligand Activated Therapy (LAT) approach?
Which areas of medical needs does Zevra's technology target?
Who are the primary contacts for investor relations?
How does Zevra ensure the financial stability of their projects?
What recent achievements has Zevra made?
What kind of partnerships does Zevra engage in?
How can stakeholders stay updated with Zevra's latest news?
What is the significance of Zevra’s prodrug development?
